Novo Challenges Lilly With Up To $2B Bet for Triple-G Obesity Drug From Chinese Biotech

By /

Novo will license UTB251, a triple hormone receptor agonist that in mid-2023 achieved promising weight reduction in a mid-stage study.

Scroll to Top